Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality | Cardiovascular Diabetology

  • Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–42.

    PubMed 

    Google Scholar 

  • Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197–213.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Han E, Han KD, Lee YH, Kim KS, Hong S, Park JH, Park CY. Fatty liver and diabetes statistics in Korea: nationwide data 2009 to 2017. Diabetes Metab J. 2023;47(3):347–55.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim JY, Lee J, Moon JH, Park SE, Ko SH, Choi SH, Kim NH. Prevalence, incidence, and metabolic characteristics of young adults with type 2 diabetes mellitus in South Korea (2010–2020). Diabetes Metab J. 2025;49(2):172–82.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Stefan N, Yki-Jarvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134–48.

    CAS 
    PubMed 

    Google Scholar 

  • Stefan N, Targher G. Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine. Nat Rev Gastroenterol Hepatol. 2025;22(4):226–7.

    PubMed 

    Google Scholar 

  • Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina RM, Alvarez M, Gelev K, Maurotti S, Vespasiani-Gentilucci U, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(12):3614–23.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, Qadri SF, Caiazzo R, Verkindt H, Saponaro C, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(12):3624–33.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Alkhouri N, Hanouneh IA, Zein NN, Lopez R, Kelly D, Eghtesad B, Fung JJ. Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int. 2016;29(4):418–24.

    CAS 
    PubMed 

    Google Scholar 

  • Han E, Lee YH, Kim YD, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol. 2020;115(4):584–95.

    PubMed 

    Google Scholar 

  • Jung I, Koo DJ, Lee WY. Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: clinical and experimental perspective. Diabetes Metab J 2024; 48: 327.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612.

    PubMed 

    Google Scholar 

  • Stefan N, Schick F, Birkenfeld AL, Haring HU, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023;35(2):236–52.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.

    CAS 
    PubMed 

    Google Scholar 

  • Han E, Lee BW, Kang ES, Cha BS, Ahn SH, Lee YH, Kim SU. Mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based cohort study. Metabolism. 2024;152:155789.

    CAS 
    PubMed 

    Google Scholar 

  • Park H, Yoon EL, Cho S, Jun DW, Nah EH. Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease. Gut. 2022;71(5):1035–6.

    PubMed 

    Google Scholar 

  • Han E, Han KD, Lee BW, Kang ES, Cha BS, Ko SH, Lee YH. Severe hypoglycemia increases dementia risk and related mortality: a nationwide, population-based cohort study. J Clin Endocrinol Metab. 2022;107(5):e1976–86.

    PubMed 

    Google Scholar 

  • Kim KS, Kim B, Han K. Big data research for diabetes-related diseases using the Korean National health information database. Diabetes Metab J. 2025;49(1):13–21.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Han E, Lee JY, Han KD, Cho H, Kim KJ, Lee BW, Kang ES, Cha BS, Younossi ZM, Lee YH. Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. Sci Rep. 2020;10(1):6800.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim MK, Han K, Lee SH. Current trends of big data research using the Korean National health information database. Diabetes Metab J. 2022;46(4):552–63.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Perazzo H, Pacheco AG, Griep RH. Collaborators: changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J Hepatol. 2024;80(2):e72–4.

    PubMed 

    Google Scholar 

  • Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201–4.

    PubMed 

    Google Scholar 

  • Moon JS, Kang S, Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, Seo JA, Kim MK, et al. 2023 clinical practice guidelines for diabetes management in Korea: full version recommendation of the Korean diabetes association. Diabetes Metab J. 2024;48(4):546–708.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Jeong SM, Jeon KH, Shin DW, Han K, Kim D, Park SH, Cho MH, Lee CM, Nam KW, Lee SP. Smoking cessation, but not reduction, reduces cardiovascular disease incidence. Eur Heart J. 2021;42(40):4141–53.

    PubMed 

    Google Scholar 

  • Kimm H, Yun JE, Lee SH, Jang Y, Jee SH. Validity of the diagnosis of acute myocardial infarction in Korean National medical health insurance claims data: the Korean heart study (1). Korean Circ J. 2012;42(1):10–5.

    PubMed 
    PubMed Central 

    Google Scholar 

  • WHO. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: International Diabetes Institute, Regional Office for the Western Pacific; 2000.

    Google Scholar 

  • Park SE, Ko SH, Kim JY, Kim K, Moon JH, Kim NH, Han KD, Choi SH, Cha BS. Diabetes fact sheets in Korea 2024. Diabetes Metab J. 2025;49(1):24–33.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Bae J, Han E, Lee HW, Park CY, Chung CH, Lee DH, Cho EH, Rhee EJ, Yu JH, Park JH, et al. Metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: a review and position statement of the fatty liver research group of the Korean diabetes association. Diabetes Metab J. 2024;48(6):1015–28.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962–9.

    CAS 
    PubMed 

    Google Scholar 

  • Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372–82.

    CAS 
    PubMed 

    Google Scholar 

  • Bae JC, Han JM, Cho JH, Kwon H, Park SE, Park CY, Lee WY, Oh KW, Kwon S, Park SW, et al. The persistence of fatty liver has a differential impact on the development of diabetes: the Kangbuk Samsung health study. Diabetes Res Clin Pract. 2018;135:1–6.

    PubMed 

    Google Scholar 

  • Fukuda T, Hamaguchi M, Kojima T, Mitsuhashi K, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol. 2016;28(12):1443–9.

    CAS 
    PubMed 

    Google Scholar 

  • Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98(9):3637–43.

    CAS 
    PubMed 

    Google Scholar 

  • Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38(9):1673–9.

    CAS 
    PubMed 

    Google Scholar 

  • Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58(11):1538–44.

    CAS 
    PubMed 

    Google Scholar 

  • Simon TG, Roelstraete B, Hartjes K, Shah U, Khalili H, Arnell H, Ludvigsson JF. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol. 2021;75(5):1034–41.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaikkonen JE, Wurtz P, Suomela E, Lehtovirta M, Kangas AJ, Jula A, Mikkila V, Viikari JS, Juonala M, Ronnemaa T, et al. Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the young Finns study. Hepatology. 2017;65(2):491–500.

    CAS 
    PubMed 

    Google Scholar 

  • Han E, Lee YH. Non-alcoholic fatty liver disease: the emerging burden in cardiometabolic and renal diseases. Diabetes Metab J. 2017;41(6):430–7.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States. J Hepatol. 2024;80(2):e79–81.

    PubMed 

    Google Scholar 

  • Kim KS, Hong S, Ahn HY, Park CY. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study. Diabetes Metab J. 2023;47(2):220–31.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024;384:e076388.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Continue Reading